Narrative review discusses PROTACs for oncology, immune modulation, and neurodegenerative diseases with noted limitations

This narrative review explores the potential of PROTACs across oncology, immune modulation, and neurodegenerative diseases. The scope covers the current state of PROTAC technology and its theoretical applications in these therapeutic areas. No specific population, sample size, or setting details are provided in this source. The review synthesizes existing knowledge without reporting primary outcome data or adverse events.

The authors identify several key limitations that currently hinder the clinical translation of PROTACs. These include suboptimal pharmacokinetic profiles and the stoichiometric hook effect, which can limit efficacy. Furthermore, there is a disproportionate reliance on a limited pool of E3 ligases, specifically cereblon and von Hippel-Lindau. This dependency restricts the diversity of available targets and may impact the breadth of potential treatments.

The review does not report specific safety data, tolerability, or discontinuation rates. Consequently, the practice relevance regarding patient management or immediate clinical adoption remains unclear. The authors note these gaps, emphasizing that the technology is still in early development stages. Clinicians should interpret these findings as preliminary insights rather than established clinical guidelines.